Autoimmune Disorders Stocks List Ranked for 2024 |

Autoimmune Disorders ETFs
Recent Autoimmune Disorders News

Symbol	Grade	Name	% Change
BNTX	D	BioNTech SE	0.85
BIIB	D	Biogen Idec Inc.	-2.24
STRO	D	Sutro Biopharma, Inc.	5.60
ALVO	D	Alvotech	1.12
CGEN	D	Compugen Ltd.	-3.17
IMAB	F	I-Mab	-2.75
CUE	F	Cue Biopharma, Inc.	6.10
PLX	F	Protalix BioTherapeutics, Inc.	3.54
VTYX	F	Ventyx Biosciences, Inc.	18.85
TRIB	F	Trinity Biotech plc	2.61

View As Page of Charts

Related ETFs - A few ETFs which own one or more of the above listed Autoimmune Disorders stocks.

Symbol	Grade	Name	Weight
FBT	C	First Trust Amex Biotech Index Fund	7.12
BBH	B	Market Vectors Biotech ETF	6.78
GERM	C	ETFMG Treatments Testing and Advancements ETF	6.32
BIS	F	ProShares UltraShort Nasdaq Biotechnology	6.12
IBB	B	iShares Nasdaq Biotechnology Index Fund	5.17

View all Autoimmune Disorders ETFs...

Compare ETFs

Compare BBH to IBB Compare BIS to IBB Compare GERM to IBB

Autoimmune Disorders Stocks Recent News

Date	Stock	Title
May 16	VTYX	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
May 16	BIIB	Biogen also drops collaboration with Ionis on Angelman syndrome candidate
May 16	BIIB	Biogen and Ionis drop ALS candidate after trial setback
May 16	VTYX	Ventyx Biosciences gets new operations chief
May 16	BIIB	Biogen, Ionis shelve ALS drug following study failure
May 16	VTYX	Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
May 16	BIIB	REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
May 16	BIIB	Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16	BIIB	Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16	CGEN	Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
May 15	BIIB	Eisai projects major growth for Alzheimer's therapy Leqembi
May 15	BIIB	Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
May 15	PLX	PLX: First Quarter Update
May 15	BIIB	Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
May 15	BIIB	Eisai sets new revenue target for Alzheimer’s drug Leqembi
May 15	BIIB	Biogen partner Eisai begins FDA submissions for injectable Alzheimer’s therapy
May 15	CGEN	Compugen names David Silberman as finance chief
May 15	CGEN	Compugen Appoints David Silberman as Chief Financial Officer
May 15	BIIB	UPDATE 1-Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
May 14	BIIB	Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

Autoimmune Disorders: Autoimmune disorders are conditions in which the body's immune system mistakenly attacks healthy tissue. This can cause a wide range of symptoms, depending on the type of disorder and the organs or tissues affected. Common autoimmune disorders include type 1 diabetes, rheumatoid arthritis, lupus, and multiple sclerosis. Treatment typically involves medications to suppress the immune system and reduce inflammation.

Browse All Tags